Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Bowman-Birk Inhibitor Concentrate in Healthy Men

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00679094
First received: May 14, 2008
Last updated: October 7, 2014
Last verified: February 2014

May 14, 2008
October 7, 2014
June 2007
December 2009   (final data collection date for primary outcome measure)
  • Recommended phase II dose, defined as the highest dose level at which none of the subjects in that dose group experience DLT as measured by NCI Common Toxicity Criteria [ Time Frame: Up to 48 hours ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics of BBIC in the serum as measured by a sandwich enzyme-linked immunosorbent assay [ Time Frame: Immediately before BBIC administration and 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 after administration ] [ Designated as safety issue: No ]
    Presented in a form of time course of serum BBI concentration after BBIC ingestion by the study subjects and peak concentration (Cmax), time to reach peak concentration (Tmax), area under the curve (AUC), and elimination rate constant (kel) and serum half-lives (t1/2) will be calculated for each subject. Mean, median, and 95% confidence interval will then be calculated for each parameter for each dose group. The relationship between dose and the above parameters will be investigated using simple linear regression.
  • Recommended dose of Bowman-Birk Inhibitor Concentrate (BBIC) for a phase I multiple-dose BBIC study [ Designated as safety issue: Yes ]
  • Safety, including description of dose-limiting toxicity (i.e., any grade 3 event) and expansion of doses observed to be safe in humans, as measured by NCI Common Toxicity Criteria [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00679094 on ClinicalTrials.gov Archive Site
Not Provided
Pharmacokinetics of BBIC as measured by a sandwich enzyme-linked immunosorbent assay [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Bowman-Birk Inhibitor Concentrate in Healthy Men
Phase I Single Dose Safety and Pharmacokinetic Study of a New Formulation of Bowman Birk Inhibitor Concentrate, Delivered as an Orange Juice Suspension to Healthy Male Volunteers Between 18 and 65 Years of Age

This randomized phase I trial is studying the side effects and best dose of Bowman-Birk inhibitor concentrate in healthy men. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of Bowman-Birk inhibitor concentrate may prevent cancer.

OBJECTIVES:

I. Assess the toxicity of single-dose Bowman-Birk Inhibitor Concentrate (BBIC) when administered as a suspension in orange juice in healthy male participants.

II. Determine the appropriate dose range and doses to be used in a subsequent phase I multiple-dose BBIC study that will be based upon the data gathered from this phase I single-dose study.

III. Characterize the pharmacokinetics of single-dose BBIC.

OUTLINE: This is a dose-escalation study of Bowman-Birk Inhibitor Concentrate (BBIC). Participants are sequentially assigned to 1 of 4 dose level cohorts. One participant in each dose level cohort is randomized to receive placebo or BBIC.

Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.

Participants undergo blood and urine sample collection periodically for pharmacokinetic studies. Samples are analyzed by a sandwich enzyme-linked immunosorbent assay to measure concentrations of BBIC and its metabolites in serum and urine.

After completion of study treatment, participants are followed once weekly for 4 weeks.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Healthy, no Evidence of Disease
  • Drug: Bowman-Birk inhibitor concentrate
    Given orally
    Other Name: BBIC
  • Other: placebo
    Given orally
    Other Name: PLCB
  • Other: pharmacological study
    Correlative studies
    Other Name: pharmacological studies
  • Other: laboratory biomarker analysis
    Correlative studies
Experimental: Arm I
Participants receive a single dose of oral BBIC or placebo, as an orange juice suspension, immediately followed by consumption of a defined low-fat breakfast. Participants continue to consume a low-fat diet for the next 48 hours and then resume their normal diet.
Interventions:
  • Drug: Bowman-Birk inhibitor concentrate
  • Other: placebo
  • Other: pharmacological study
  • Other: laboratory biomarker analysis
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
December 2009
December 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male participant recruited from the Philadelphia, Pennsylvania metropolitan area
  • ECOG performance status 0-2
  • WBC ≥ 3,000/uL
  • Differential (i.e., neutrophils, lymphocytes, monocytes, bands, eosinophils, and basophils) normal
  • Platelet count normal
  • Hemoglobin normal
  • Hematocrit normal
  • RBC normal
  • Creatinine normal
  • Bilirubin normal
  • ALT and AST normal
  • Amylase and lipase normal
  • Glucose normal
  • Cholesterol normal
  • Triglycerides normal
  • Non-smoker

    • Former smokers are eligible provided they have not smoked within the past 3 months
  • Within 15% of ideal body weight based on standard weight tables
  • No vegetarians or individuals who normally ingest large amounts of soy products, defined as two or more servings of tofu, soy milk, or other primarily soy-based food per day
  • No prior allergy or adverse reaction to soybeans
  • No diagnosis of cancer within the past 5 years except nonmelanoma skin cancer
  • No prior diagnosis of pancreatitis, pancreatic carcinoma, pancreatic adenoma, diabetes mellitus, obstruction of pancreatic ducts, or amyloidosis
  • No history of heart disease
  • EKG normal (normal variants allowed)
  • No evidence of psychiatric problems
  • No history of excessive alcohol consumption (i.e., an average of > 2 alcoholic beverages per day)
  • No alcohol consumption within the past 3 days
  • No history of any medical condition that could influence gastrointestinal uptake of the drug
  • No history of chronic medical condition
  • No evidence of another life-threatening disease
  • More than 12 months since prior chemotherapy
  • More than 1 month since prior experimental drugs
  • More than 2 weeks since prior and no concurrent regular use (i.e., > 3 times/week) of nonsteroidal anti-inflammatory drugs (NSAIDs)
  • More than 2 weeks since prior and no concurrent multivitamin tablets (or other vitamin supplements) of > 2 per day
Male
18 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00679094
NCI-2009-00865, NCI-2009-00865, CDR0000595863, UPCC-N01-CN-25118-2, UPCC-805938, UPCC-805938, N01-CN-25118-2, P30CA016520, N01CN25118
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Lilie Lin Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP